PI3K/Akt survival signaling is supplemented by the survival signaling of NF-κB, suggesting that targeting both pathways in a joint manner may be highly effective in limiting MCL cell proliferation and preventing tumor growth in patients. The gene discussed is PIK3CA; the disease is neoplasm.